RIFAROOT-400

Product Introduction RIFAROOT-400

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller?s diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.

Rabeprazole, a PPI that inhibits acid & Levosulpiride, an anti-psychotic & Prokinetic drug that increases the movement in GI tract. It is indicated in the treatment of gastroesophageal reflux disease (GERD) in Patients who do not respond to monotherapy with PPI?s. It is also indicated in Zollinger-Ellison syndrome, gastric and duodenal ulcers.

Indication of RIFAROOT-400

Rifaximin, a rifamycin derivative that acts locally in the intestine and specifically used in intestinal infections of various kinds. It is prescribed for traveler?s diarrhoea, irritable bowel syndrome, buldges in the intestine & auto-immune disease of the small and large intestines.

Side Effects

Abdominal pain, Abdominal distension, Diarrhoea, Nausea, Vomiting, Dizziness, Headache, Depression, Dsypnoea, Rashes, Pruritus, Muscle spasms, Joint pain & peripheral Oedema are the few side effect.